Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.

medRxiv : the preprint server for health sciences·2025

Same author

Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets.

NPJ breast cancer·2025

Same author

Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702.

Leukemia·2025

Same author

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024

Same author

Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple Myeloma.

American journal of clinical oncology·2024

Same author

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.

Cancer immunology, immunotherapy : CII·2023

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Second malignancies after allogeneic hematopoietic cell transplantation.

Thomas Lowe¹, Smita Bhatia, George Somlo

¹City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA. tlowe@coh.org

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation

|September 25, 2007

Summary

Allogeneic hematopoietic cell transplantation (allo-HCT) survivors face increased risks of second cancers, particularly post-transplant lymphoproliferative disorder and solid tumors. Vigilant monitoring and screening are crucial for managing these long-term complications.

More Related Videos

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Related Experiment Videos

Last Updated: Jul 11, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Area of Science:

Hematology
Oncology
Transplantation Immunology

Background:

Allogeneic hematopoietic cell transplantation (allo-HCT) offers life-saving treatment for fatal diseases.
Long-term survivors of allo-HCT are at risk for significant late complications, notably second malignancies.
The incidence and management of these secondary cancers require careful consideration.

Purpose of the Study:

To highlight the increased risk of second malignancies following allo-HCT.
To emphasize the importance of recognizing specific types of post-transplant cancers, including PTLD and SSM.
To advocate for improved surveillance and management strategies for allo-HCT survivors.

Main Methods:

Review of existing literature and clinical observations regarding second malignancy incidence after allo-HCT.
Analysis of risk factors and latency periods for various second malignancies.
Discussion of current challenges and recommendations for future care.

Main Results:

Allo-HCT significantly increases the risk of post-transplant lymphoproliferative disorder (PTLD), often EBV-associated, and second solid malignancies (SSM).
While treatment-related MDS and secondary leukemias are rare, SSM incidence rises over time, potentially linked to radiation exposure.
Long-term follow-up reveals a cumulative increase in SSM, necessitating ongoing surveillance.

Conclusions:

Systematic monitoring, screening, and dedicated survivorship care are essential for allo-HCT recipients.
Development of clear guidelines for screening and prevention of second malignancies is urgently needed.
Physician awareness and proactive patient management are critical for improving long-term outcomes after allo-HCT.